Myeloid Cell Plasticity Emerges as a Key Target for Next-Gen Cancer Therapies
A new review reframes how myeloid cells fuel or fight tumors, pointing to plasticity — not just cell diversity — as the core therapeutic target.
Summary
Myeloid cells are immune cells that play a complicated double role in cancer — sometimes helping tumors grow and sometimes fighting them. Scientists have long assumed this was because different subtypes of myeloid cells exist within tumors. This review challenges that assumption, arguing that 'plasticity' — the ability of individual myeloid cells to shift their behavior — is actually the more fundamental driver. The authors identify two forms of this plasticity: one involving how myeloid cells develop (differentiation plasticity) and one involving how they function once mature (functional plasticity). Understanding these mechanisms could help explain why many current cancer immunotherapies fail, and opens new avenues for treatments that reprogram myeloid cells rather than simply trying to block or deplete them.
Detailed Summary
Cancer immunotherapy has transformed oncology, yet a large proportion of patients still fail to respond to existing treatments. One underappreciated reason may be the behavior of myeloid cells — a broad class of immune cells including macrophages, neutrophils, and dendritic cells — that infiltrate tumors in large numbers. Their dual capacity to either suppress or stimulate anti-tumor immunity has long puzzled researchers and clinicians alike.
This review from AstraZeneca researchers, published in Nature Cancer, proposes a paradigm shift. Rather than attributing the contradictory behavior of tumor-associated myeloid cells solely to heterogeneity among distinct cell subtypes, the authors argue that plasticity — the intrinsic capacity of myeloid cells to dynamically reprogram themselves — is the more fundamental and clinically relevant trait.
The authors describe two distinct forms of this plasticity. Differentiation plasticity refers to systemic changes in myeloid cell production and maturation, including accelerated myelopoiesis and altered developmental trajectories that generate immunosuppressive cell populations. Functional plasticity refers to the adoption of pathological activation states by mature myeloid cells in response to tumor-derived signals, effectively co-opting normal immune machinery to shield the tumor.
Recognizing plasticity as central rather than peripheral changes the therapeutic calculus considerably. Instead of targeting fixed cell populations, future strategies may need to intercept the signaling pathways that drive pathological reprogramming — a more dynamic and adaptive challenge. The authors evaluate existing myeloid-targeting approaches and propose flexible therapeutic frameworks designed to account for this plasticity.
Several caveats apply. This is a narrative review from researchers employed by AstraZeneca, introducing potential industry bias. The summary is based on the abstract alone, limiting assessment of the strength of evidence cited. Nevertheless, the conceptual reframing offered here has direct implications for how next-generation immuno-oncology combination therapies are designed and tested.
Key Findings
- Myeloid cell plasticity — not just cell-type heterogeneity — is identified as the primary driver of tumor immune evasion.
- Two plasticity types are defined: differentiation plasticity (altered myelopoiesis) and functional plasticity (pathological activation states).
- Current myeloid-targeting therapies may be failing partly because they address fixed cell populations rather than dynamic reprogramming.
- Adaptable therapeutic strategies that intercept myeloid reprogramming signals are proposed as a more effective approach.
- Tumor-associated myeloid cells promote angiogenesis, metastasis, and immune suppression while also retaining antitumor potential.
Methodology
This is a narrative review article published in Nature Cancer, authored by oncology researchers at AstraZeneca. It synthesizes existing literature on myeloid cell biology and cancer immunology to propose a conceptual framework around myeloid plasticity and its therapeutic implications. No original experimental data are presented.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, limiting evaluation of the evidence base and specific claims. All three authors are employees and shareholders of AstraZeneca, which introduces potential commercial bias in framing therapeutic strategies. As a narrative review, it does not include systematic evidence synthesis or meta-analytic methods.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.